{"entity":{"id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","aka":["major pathologic response","≤10% viable tumour"],"tldr":"When, after pre-surgery treatment, the removed tumour contains little or no living cancer: 10% or less viable cells.","summary":"Defined by the International Neoadjuvant Melanoma Consortium as ≤10% viable tumour (pathological complete response is 0%). In NADINA and earlier OpCACI trials, MPR predicted very low relapse risk and was used to decide whether adjuvant therapy could be omitted. The melanoma analogue of pCR in breast cancer.","asOf":"2026-09-07","links":[{"label":"INMC pathological assessment after neoadjuvant therapy for melanoma (Tetzlaff et al., Ann Oncol 2018)","url":"https://doi.org/10.1093/annonc/mdy226"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pcr","neoadjuvant-adjuvant"],"trials":["nadina"],"people":[],"bottlenecks":[],"keyPapers":["paper-tetzlaff-ann-oncol"],"journals":[],"dependsOn":[],"notes":[],"category":"Endpoints","wikipediaChecked":"2026-09-22"},"route":"/terms/major-pathological-response/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"term":[{"id":"interferon-gamma-signature","kind":"term","name":"Interferon-gamma gene signature (T-cell-inflamed signature)","route":"/terms/interferon-gamma-signature/"},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"}],"trial":[{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/"},{"id":"neotorch","kind":"trial","name":"Neotorch","route":"/trials/neotorch/"}],"paper":[{"id":"paper-tetzlaff-ann-oncol","kind":"paper","name":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","route":"/key-papers/paper-tetzlaff-ann-oncol/"}],"pairing":[{"id":"neoadjuvant-io-response-adapted","kind":"pairing","name":"Neoadjuvant immunotherapy → response-adapted adjuvant","route":"/pairings/neoadjuvant-io-response-adapted/"}],"idea":[{"id":"idea-tr2-neoadjuvant-combo-platform","kind":"idea","name":"Pre-surgery platform trials that test combinations on pathological response in months","route":"/ideas/idea-tr2-neoadjuvant-combo-platform/"},{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/"},{"id":"idea-bio2-neoadjuvant-biomarker-engine","kind":"idea","name":"Use pre-surgery immunotherapy windows as the field's biomarker engine","route":"/ideas/idea-bio2-neoadjuvant-biomarker-engine/"}]}}